Epilepsy and seizure disorders
Biohaven Therapeutics Ltd. funds clinical research in refractory focal onset epilepsy and idiopathic generalized epilepsy with generalized tonic-clonic seizures, with attention to seizure control, treatment response, and overall safety in adults living with difficult-to-manage epileptic conditions.
- Refractory focal onset epilepsy
- Idiopathic generalized epilepsy with generalized tonic-clonic seizures
- Antiseizure therapy
The sponsor’s epilepsy portfolio reflects interest in therapies aimed at reducing seizure burden and addressing unmet needs in chronic neurological disorders.
Parkinson’s disease
The company also supports studies in early Parkinson’s disease, focusing on clinical outcomes linked to motor and functional impairment and the potential to slow worsening in everyday activities.
- Early Parkinson’s disease
- Movement disorder
- Functional decline
This area of interest places emphasis on neurodegenerative disease management and symptom-related disability.
Pain and analgesic research
Biohaven Therapeutics Ltd. has research activity in pain treatment, including evaluation of candidate therapies for analgesic use and tolerability in healthy participants, indicating interest in both pain relief and central nervous system-related pharmacology.
- Pain
- Analgesic therapy
- Central nervous system pharmacology
The sponsor’s pain-related work connects to broader efforts in neurology and symptom management.
Therapeutic development in neurology
Across its funded studies, the sponsor’s clinical research landscape is centered on neurological disease areas where treatment options are limited, including epilepsy, Parkinson’s disease, and pain-related conditions.
- Neurological disorders
- Seizure disorders
- Neurodegenerative disease
Its portfolio includes work relevant to adult patients with chronic conditions requiring sustained therapeutic management.
